Key result
LDL amplifies cytokine signaling in CLL cells via lysosomal breakdown.
Why the study?
The mechanisms by which elevated LDL levels affect CLL cells and the patient subgroups they impact are unclear.
Does LDL exposure enhance proliferative responses of CLL cells to inflammatory signals?
Does LDL exposure enhance proliferative responses of CLL cells to inflammatory signals?
LDLs amplify cytokine signaling and proliferation in CLL cells, suggesting a potential mechanism for the observed survival benefit of statins in CLL patients.
LDL effects on CLL cytokine signaling remain preclinical; leaves open statin mechanisms and requires human validation before any practice implications.
Recent studies suggest there is a high incidence of elevated low-density lipoprotein (LDL) levels in Chronic Lymphocytic Leukemia (CLL) patients and a survival benefit from cholesterol-lowering statin drugs. The mechanisms of these observations and the kinds of patients they apply to are unclear. Using an in vitro model of the pseudofollicles where CLL cells originate, LDLs were found to increase plasma membrane cholesterol, signaling molecules such as tyrosine-phosphorylated STAT3, and activated CLL cell numbers. The signaling effects of LDLs were not seen in normal lymphocytes or glycolytic lymphoma cell-lines but were restored by transduction with the nuclear receptor PPARδ, which mediates metabolic activity in CLL cells. Breakdown of LDLs in lysosomes was required for the amplification effect, which correlated with down-regulation of HMGCR expression and long lymphocyte doubling times (LDTs) of 53.6±10.4months. Cholesterol content of circulating CLL cells correlated directly with blood LDL levels in a subgroup of patients. These observations suggest LDLs may enhance proliferative responses of CLL cells to inflammatory signals. Prospective clinical trials are needed to confirm the therapeutic potential of lowering LDL concentrations in CLL, particularly in patients with indolent disease in the "watch-and-wait" phase of management.
No takes yet. Share an insight, caveat, or question.
McCaw et al. (2016) studied Chronic Lymphocytic Leukemia. Low-density lipoproteins (LDL) was evaluated on Plasma membrane cholesterol, signaling molecules, and activated CLL cell numbers. Low-density lipoproteins amplified cytokine signaling in chronic lymphocytic leukemia cells, an effect requiring lysosomal breakdown and correlating with lymphocyte doubling times of 53.6±10.4 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: